Drugs / ADCT-701
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | pediatric neuroendocrine cancers | 2023-11-14 | “ADCT-701の米国での臨床第1相試験に向けてIND申請完了” xj-storage.jp ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06041516 | Jun 2024 → Oct 2027 expected | adrenal cortex carcinoma, neuroendocrine carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCT-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06041516 ↗ |
| Route | Intravenous | “ADCT-701 given as an IV infusion” NCT06041516 ↗ |
| Target | DLK1 | “ADCT-701 a humanized antibody directed against DLK1 effectively suppresses tumor growth” NCT06041516 ↗ |